A breakthrough in lung cancer care?
Robotic-assisted surgery is becoming a major advance in lung cancer care. It supports faster recovery and fewer complications, with potential survival benefits for patients and the NHS. Could this be the breakthrough lung cancer needs?
A systematic review covering over 50,000 patients showed that robotic-assisted thoracic surgery improved disease-free survival by 24% compared with VATS¹.
The analysis reported a 45% reduction in 30-day mortality. This reinforces the clinical value of a precise, minimally invasive approach.
In the UK, the economic case for robotic-assisted lung surgery is becoming clear. A recent cost-effectiveness study found that robotic-assisted lobectomy delivered an extra 0.5 QALYs per patient. The additional cost was £2,793 over five years, well below the NHS cost-effectiveness threshold².
Creating capacity in pressured hospitals
At Guy’s and St Thomas’ NHS Foundation Trust, surgeon Tom Routledge has seen the impact first-hand. Robotic-assisted lung surgery has cut average hospital stays from four days to two³. This frees up beds and helps teams treat more patients.
Together, these trends point to growing confidence in robotic-assisted technology. Across the NHS, use has risen more than sixfold since 2017, a 626% increase as more Trusts invest.⁴
The benefits go beyond patients. Robotic-assisted systems give surgeons greater precision, reduce physical strain, and support workforce sustainability during a time of staffing pressure.
For patients, the difference can be life-changing. Smaller incisions and less trauma reduce pain and complications. Many patients return to daily life sooner and are discharged in days, not weeks.
Samantha’s story
Samantha Knight, 33, from Rochdale, underwent robotic-assisted surgery in 2024. For her, the operation didn’t just save her life — it gave her the chance to continue living on her own terms.
“The position of my tumour meant an open procedure would likely have required removing my entire lung. That would have ended my career as a cabin crew member, as I wouldn’t have been able to work at altitude.
“Robotic-assisted surgery made all the difference. My surgeon removed just one lobe, and within three months, I was back at work, back in the air, and living the same life I had before my diagnosis.”
For the NHS, the technology can help to bring shorter recovery times, fewer readmissions, and improved theatre productivity. Together, these outcomes point to a better patient experience and a more sustainable way to deliver complex cancer care.
A call for fair access and investment
Paula Chadwick, Chief Executive of Roy Castle Lung Cancer Foundation, said:
“Robotic-assisted surgery offers real hope — for patients, for families, and for our health service. The data is clear: it’s clinically effective, cost-effective, and transformative. The challenge now is ensuring that everyone who could benefit, does.”
Roy Castle Lung Cancer Foundation is calling for sustained investment in robotic-assisted surgery across NHS thoracic centres. This must be backed by dedicated training programmes to expand access and ensure equity across the UK.
Alongside this, the charity urges stronger integration of robotic-assisted surgery across the lung cancer pathway.This includes linking it with early detection and screening to maximise survival gains.
Looking ahead for the NHS and patients
As the NHS modernises and looks for efficiencies, robotic-assisted lung cancer surgery is becoming more important. It offers greater precision, better use of resources, and improved care for patients.
- A systematic review of 25 studies covering more than 50,000 patients, compared robotic surgery with VATS. Robotic-assisted thoracic surgery was linked to a 24% improvement in disease-free survival and a 45% reduction in 30-day mortality.. (PubMed: 33367615)
- A cost-effectiveness analysis found that robotic lobectomy for non-small cell lung cancer delivered an additional 0.5 quality-adjusted life years. This came at an incremental cost of £2,793 over five years, giving an ICER of around £5,586 per QALY. (ISPOR Europe 2024)
- Hospital stay reduction: Surgeon Tom Routledge, Guy’s and St Thomas’ NHS Foundation Trust in an interview with the Dily Express. (NHS robot surgery revolution ‘will help cut waiting times’)
- UK adoption growth: Robot-assisted procedures in the NHS increased by 626% from 2017–2024. (PHIN UK Report)